Cytotherapy Editorial Board

About


Cytotherapy, the official journal of the  ISCT, publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. Studies evaluating the potency of experimental cell and gene therapies in clinically relevant animal models of disease and describing important advances in cell/gene-based product manufacturing and validation are welcomed. Results of clinical studies evaluating the safety and efficacy of cell and gene therapies in early and late phase trails are also of interest. In addition to short reports and full-length articles, the journal also accepts editorials addressing emerging trends and potential controversies in the field, and review articles summarizing bodies of work that have made lasting impacts in the field.

The journal's scope includes research in the following:

  • Stem cell processing and transplantation
  • Cell-based therapies of malignant and non-malignant blood diseases
  • Cancer
  • Stem cell plasticity
  • Autoimmune diseases
  • Immunotherapy
  • Congenital disorders
  • Novel molecular therapies
  • Gene therapy
  • Microvesicle biology and therapeutic application

Readership and Target Group

Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists and immunologists, and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.

Keywords

Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.

Submission Details

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt whether the manuscript is accepted, requires revision or is rejected. All manuscripts will be published within five months from the date of acceptance. Contributors should submit manuscripts via: http://mc.manuscriptcentral.com/cytotherapy.

 

CLICK HERE to access Cytotherapy

  

Donald Phinney, PhD
Senior Editor

Professor at The Scripps Research Institute
Jupiter, FL, United States


                    

 

Associate Editors:

 
Massimo Dominici, MD
University of Modena and Reggio
Modena, Italy


John Rasko, AO, MBBS, PhD, FRCPA, FRACP, FAHMS
Royal Prince Alfred Hospital
Sydney, Australia

   

Luis Ortiz, MD
University of Pittsburgh
Pittsburgh, PA, United States

Oscar Lee, MD, PhD
National Yang- Ming University
Taiwan
   

Sowmya Viswanathan, PhD
Cell Therapy Program, University Health Network
Toronto, ON, Canada

 

 

Editorial Board
The editors are supported by an international editorial board made up of over 35 eminent academics in the field.

Angela Welch
Publisher, Cytotherapy

Join us on Cytotherapy's LinkedIn and Elsevier's Hematology accounts on Twitter and Facebook:

LinkedIn Twitter Facebook

 

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy